TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06470191: A Multicenter, Randomized, Controlled, Open Phase II/III Clinical Study to Evaluate the Efficacy and Safety of B007 Versus Cyclosporine in the Treatment of Primary Membranous Nephropathy.

Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd · Phase: PHASE2/PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 216 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,207,008

Rescue Site Savings

+$6,723,664

Unlock Full NCT06470191 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06470191 Rescue Dossier →